AP-201

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAP-201

Drug Alias NameAP-201

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonistsProgrammed death-ligand 1 blockers

TargetsTumor necrosis factor receptor superfamily member 4Programmed death-ligand 1

Therapy Area/IndicationsHead and Neck NeoplasmsOvarian NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAP Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesAP Biosciences Inc Tasly Biomedical Co Ltd

Inactive CompaniesN/A

Active IndicationsHead and Neck NeoplasmsOvarian NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A